AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Viking Therapeutics shares fall 21.36% in premarket after announcing positive results for VK2735 in obesity trial.
ByAinvest
Tuesday, Aug 19, 2025 7:17 am ET1min read
Viking Therapeutics, Inc. plunged 21.36% in premarket trading, following the announcement of positive results from the VENTURE-Oral Phase 2 trial of its oral VK2735 for obesity, with an average weight loss of 12.2% over 13 weeks compared to 1.3% for the placebo. The company is a clinical-stage biopharmaceutical company focused on developing new therapies for metabolic and endocrine disorders, with its GLP-1/GIP dual agonist VK2735 advancing in oral and subcutaneous formulations for obesity treatment. The weight loss drug sector was boosted by the FDA approval of a new indication for Novo Nordisk's Wegovy, indirectly lifting related stocks today.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet